We are a clinical-stage oncology company dedicated to developing best-in-class small molecule therapies that can make a difference for patients suffering from rare and aggressive cancers.
Our lead product candidates, AL101 and AL102, have the potential to tackle cancer by inhibiting Notch pathway activation with gamma secretase inhibitors (GSIs).
Through a combination of our bioinformatics platform and next generation sequencing, we’re enabling a novel approach to cancer treatment.
We tackle cancers driven by Notch pathway activation
In cancers, Notch serves as a critical facilitator of cell proliferation, survival, drug resistance and metastatic spread. Our goal is to overcome Notch activity with product candidates designed to address tumor growth driven by Notch pathway activation.
Every patient is different
Our development approach is rooted in identifying and addressing indications in which Notch is a known tumorigenic driver. Using a combination of our bioinformatics platform and next generation sequencing, we are developing targeted therapies to underserved patient populations where gamma secretase inhibition of Notch can lead to clinical benefit.